Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Wdr26 insufficiency causes Skraban-Deardorff syndrome–like neurodevelopmental deficits in mice
Xingyun Xu, Yaohui Zhou, Shiyao Xu, Hongjie Zhou, Xuexia Lin, Yuhao Luo, Yu Xu, Zhigang Miao, Wei Ge, Hao Yang, Xingshun Xu
Xingyun Xu, Yaohui Zhou, Shiyao Xu, Hongjie Zhou, Xuexia Lin, Yuhao Luo, Yu Xu, Zhigang Miao, Wei Ge, Hao Yang, Xingshun Xu
View: Text | PDF
Research Article Development Neuroscience

Wdr26 insufficiency causes Skraban-Deardorff syndrome–like neurodevelopmental deficits in mice

  • Text
  • PDF
Abstract

Skraban-Deardorff syndrome, a rare neurodevelopmental disorder caused by WD repeat domain 26 (WDR26) haploinsufficiency, is characterized by intellectual disability, seizures, autistic-like behaviors, and craniofacial anomalies. Despite its genetic association with variants disrupting the C-terminal to LisH (CTLH) E3 ubiquitin ligase complex, the molecular mechanisms linking WDR26 dysfunction to neurodevelopmental deficits remain unclear. Here, we demonstrate that Wdr26 heterozygous-KO mice (Wdr26+/–) recapitulated core clinical features of the syndrome, including learning and memory impairments, social dysfunction, heightened seizure susceptibility, and motor deficits, alongside rare craniofacial and dental abnormalities. Mechanistically, Wdr26 haploinsufficiency stabilized RUNX1 translocation partner 1 (RUNX1T1), a transcriptional coactivator critical for neuronal differentiation, by impairing its ubiquitination and proteasomal degradation, consequently disrupting the level of microtubule-associated protein 2 (MAP2), a key regulator of dendritic architecture and synaptic plasticity. Early intervention in neonatal Wdr26+/– mice (P0.5) using AAV-shRNA–mediated Runx1t1 knockdown reversed MAP2 overexpression and behavioral deficits. Notably, the antipsychotic risperidone ameliorated cognitive and social impairments in Wdr26+/– mice by upregulating WDR26 levels, suggesting a potential therapeutic avenue. Our findings not only establish the animal model as a robust preclinical tool but also define the WDR26/RUNX1T1/MAP2 regulatory axis as pivotal to the syndrome’s pathogenesis, while identifying actionable therapeutic targets.

Authors

Xingyun Xu, Yaohui Zhou, Shiyao Xu, Hongjie Zhou, Xuexia Lin, Yuhao Luo, Yu Xu, Zhigang Miao, Wei Ge, Hao Yang, Xingshun Xu

×

Figure 7

WDR26 interacts with RUNX1T1 to enhance its ubiquitination, thereby regulating protein levels.

Options: View larger image (or click on image) Download as PowerPoint
WDR26 interacts with RUNX1T1 to enhance its ubiquitination, thereby regu...
(A) mPFC tissues from Wdr26+/+ and Wdr26+/– mice were collected for Western blotting. (B) Quantitative analysis of RUNX1T1 protein levels (n = 5) from A. (C) N2a cells transfected with si-Wdr26 for 36 hours were tested for RUNX1T1 and WDR26 protein levels by Western blotting. (D) Quantitative analysis of WDR26 protein levels from C (n = 3). (E) Quantitative analysis of RUNX1T1 protein levels from C (n = 3). (F) N2a cells were treated with CHX, MG132, bafilomycin A1 (Baf A1), and Z-VAD-FMK (Z-V-F) for 12 hours, and RUNX1T1 protein levels were measured by Western blotting. (G) Quantitative analysis of RUNX1T1 protein levels from F (n = 3). (H) N2a cells were treated with CHX and MG132 for 2, 4, and 8 hours and RUNX1T1 protein levels were measured by Western blotting. (I) Quantitative analysis of RUNX1T1 protein levels from H (n = 3). (J and K). Immunoprecipitation analysis of WDR26 and RUNX1T1 interactions in the brains of Wdr26+/+ mice. Data are representative of 3 independent experiments. (L) Immunoprecipitation analysis of ubiquitination of RUNX1T1 in the brains of Wdr26+/+ and Wdr26+/– mouse embryos. (M) Quantitative analysis of ubiquitination levels from L (n = 3). (N) MAP2 levels in the mPFC of Wdr26+/+ and Wdr26+/– mice at P0.5 were measured by Western blotting (n = 3). Data are presented as the mean ± SEM. *P < 0.05 and **P < 0.01, by unpaired, 2-tailed Student’s t test (B, D, E, G, and M) and 2-way ANOVA with Tukey’s post hoc test for multiple comparisons (I).

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts